Calypte Biomedical and Earvin 'Magic' Johnson Commemorate World AIDS Day December 1st ALAMEDA, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that Calypte's Chairman Tony Cataldo and "Magic" Ervin Johnson spent December 1st, World AIDS Day, speaking on the importance of HIV/AIDS testing. "World AIDS Day is the ideal time for everyone to commit to being tested," said Johnson. "It's a day when we can take on the rampant spread of HIV one person at a time," he added. Calypte's Chairman Anthony Cataldo stated, "Early detection can significantly alter the quality of life, and can help prevent the spread of HIV and can ultimately save lives." Magic Johnson first appeared on NBC's Today Show followed by an interview on BET and ABC radio. Both Mr. Cataldo and Mr. Johnson appeared on MSNBC and Fox News, Your World with Neal Cavuto to discuss the company and highlight the need for HIV/AIDS testing. To access these events please go to the company's web site at http://www.calypte.com/ About The Magic Johnson Foundation The Magic Johnson Foundation was established in 1991 as a single-disease organization that worked to raise funds for community-based organizations dealing with HIV/AIDS education and prevention programs. The Foundation has since responded to the growing need to address all aspects of our youth's lives by expanding its mission. This expanded mission emphasizes the Foundation's focus on supporting community-based organizations and developing programs that serve the health, educational and social needs of those residing in inner-city communities. In addition, the Foundation has made a strong commitment to raise awareness about many of the health and social concerns that threaten under-served communities. About Calypte Biomedical Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The Company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC. Investor Relations Contact: Tim Clemensen 212-843-9337 email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Tim Clemensen, +1-212-843-9337, , for Calypte Biomedical Corporation Web site: http://www.calypte.com/

Copyright